University of Miami's 2nd Biennial Miami Leukemia Symposium

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

University of Miami's 2nd Biennial Miami Leukemia Symposium

AML Biology and Treatment
MDS Biology and Treatment
ALL Biology and Treatment
CLL Therapy in 2019
CML and MPNs: Final Frontiers and New Breakthroughs
Myeloid Biology and Novel Therapies
Event

Playback speed

10 seconds

Frontline Therapies in MDS: Leveling Lower-risk MDS

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Mikkael Sekeres

39 views

May 14, 2020

Comments 0

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

MDS Biology and Treatment

2020 Update on MDS Mutational Landscape: What Are the Most Common MD…

University of Miami's 2nd Biennial Miami Leukemia Symposium

R. Bejar

15 views

2020 Update on Splicing in MDS: How Can We Target Spliceosome-Mutant…

University of Miami's 2nd Biennial Miami Leukemia Symposium

T. Graubert

11 views

TGF Beta Pathway Inhibition in MDS: Luspatercept Significantly Decre…

University of Miami's 2nd Biennial Miami Leukemia Symposium

A. Verma

115 views

How to Calculate Risk in MDS Patients?

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Sekeres

93 views

Frontline Therapies in MDS: Leveling Lower-risk MDS

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Sekeres

39 views

Frontline Therapies in MDS: Hampering Higher-risk MDS

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Sekeres

19 views

Hypomethylating Agents as SoC in MDS/AML: Clearance of TP53 Mutation…

University of Miami's 2nd Biennial Miami Leukemia Symposium

D. Sallman

19 views

Discussion on the Data of Frontline Combination Therapy with APR-246…

University of Miami's 2nd Biennial Miami Leukemia Symposium

D. Sallman

19 views

Magrolimab (Formerly 5F9) is a First-in-class Macrophage Immune Chec…

University of Miami's 2nd Biennial Miami Leukemia Symposium

D. Sallman

168 views

Overcoming Adaptive Therapy Resistance in AML: IRAK Signalling (via …

University of Miami's 2nd Biennial Miami Leukemia Symposium

D. Starczynowski

19 views